Status:
ACTIVE_NOT_RECRUITING
Transcriptional Responses as an Indicator of Individualised Responses to Radiation Effects (RTGene 2)
Lead Sponsor:
Institute of Cancer Research, United Kingdom
Collaborating Sponsors:
Public Health England
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Peripheral blood samples will be taken with informed consent from radiotherapy patients before and during treatment fractions for sarcoma, breast, lung, gut, genitourinary and head \& neck tumours at ...
Detailed Description
Biomarkers of radiation exposure are recognised to form an important component of the 'toolkit' for initial triage assessment of potentially exposed individuals in a mass casualty radiation accident o...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Requirement for external beam radiotherapy (large-field RT, over at least 2 weeks) for sarcoma, breast, lung, gastrointestinal, head \& neck or genitourinary tumours
- Written informed consent
Exclusion
- Previous radiotherapy
- Concurrent chemotherapy/biological therapy or chemotherapy/biological therapy preceding radiotherapy by less than 4 weeks
- Concurrent hormone therapy or hormone therapy preceding radiotherapy by less than 4 weeks
Key Trial Info
Start Date :
May 9 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2026
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT03809377
Start Date
May 9 2019
End Date
June 1 2026
Last Update
October 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, United Kingdom, SM2 5PT